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Abstract
Background: Mitochondrial diabetes mellitus (MDM) is characterized by maternal inheritance, progressive neurosensory
deafness, insulin secretory disorder, and progressive microvascular complications. Mitochondria are critical organelles that provide
energy in the form of adenosine triphosphate (ATP). An impairment of ATP production in pancreatic b cells is regarded as the main
cause of the insulin secretory disorder in patients with MDM, and these patients require insulin replacement therapy early after the
diagnosis. The amino acid 5-aminolevulinic acid (5-ALA), a precursor of heme metabolites, is a non-proteinogenic d amino acid
synthesized in mitochondria. An addition of ferrous iron to 5-ALA enhances heme biosynthesis and increases ATP production
through an upregulation of the respiratory complex. Several studies have reported that the administration of 5-ALA and ferrous iron to
existing treatment improved the glycemic control in both patients with prediabetes and those with type 2 diabetes mellitus. The
additional administration of 5-ALA and ferrous iron to MDM patients on insulin therapy may improve their insulin secretory capacity
and glycemic control by improving their mitochondrial function. The findings of this study are expected to provide new treatment
options for MDM and improve the patients’ glycemic control and prognosis.
Methods/design: This study is a single-arm, open-label pilot intervention study using clinical endpoints to investigate the effects
of treatment with 5-ALA plus sodium ferrous citrate (SFC) to patients with MDM on their glucose tolerance. A total of 5 patients with
MDM will be administered 5-ALA/SFC (200mg/d) for 24weeks. We will perform a 75-g oral glucose tolerance test before and at 24
weeks after the start of this 5-ALA/SFC treatment to evaluate glucose-dependent insulin responses.
Discussion:To the best of our knowledge, this study will be the first assessment of the effects of 5-ALA/SFC in patients with MDM.
This study will obtain an evidence regarding the effectiveness and safety of 5-ALA/SFC for patients with MDM.
Trial registration: This study was registered with the University Hospital Medical Information Network (UMIN000040581) on July
1, 2020 and with the Japan Registry of Clinical Trials (jRCTs071200025) on August 3, 2020.
The trial received ethical approval on June 24, 2020. Recruitment started in August 2020, and the trial is expected to finish June 30, 2023.
The study protocol has been approved by the Certified Review Board of Nagasaki University. The reference number is CRB20-012. Fully informed written consent will
be obtained from the patients before enrollment.
Results obtained in this trial will be published in an international journal and may be presented at international scientific meetings. This information will be included in the
patient consent form.
The investigational drug (5-ALA/SFC) was provided by Neopharma Japan Co., Ltd.
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1. Introduction
Mitochondrial diseases are heterogeneous disorders character-
ized by defects of energy production via oxidative phosphory-
lation. Endocrine dysfunction is often observed in genetic
mitochondrial diseases, and among those diseases, diabetes
mellitus is the most frequently described as mitochondrial
diabetes mellitus (MDM). The m.3243 A>G mutation is the
most common point mutation of the mitochondrial deoxyribo-
nucleic acid (mtDNA) observed in patients with MDM.
However, it might be impossible to identify the mutation of
the mtDNA using the peripheral leukocytes in all patients with
MDM, because heteroplasmy values show large distributions
between individual tissues. It was reported that only 13.1%of the
blood samples were positive for the m.3243 A>G mutation
among Japanese patients withMDM.[1] Generally,MDMhas the
following characteristics.
(1) It is maternally inherited;
(2) it requires insulin therapy due to the progressive insulin
secretory disorder;
(3) it shows progressive neurosensory deafness; and
(4) it shows rapidly progressive diabetic complications.[1–4]
The current recommended treatment for MDM is only insulin
replacement therapy.
Mitochondria are critical organelles that provide energy in the
form of adenosine triphosphate (ATP) for the insulin secretory
reaction by glucose stimulation. Mitochondrial dysfunction
triggers the development of diabetes mellitus by an impairment
of ATP production, which is highly dependent on adequate heme
synthesis.[5]
The amino acid 5-aminolevulinic acid (5-ALA), a non-
proteinogenic d amino acid found in the human body, promotes
intracellular energy metabolism, and the addition of ferrous
iron to 5-ALA enhances the biosynthesis of heme, which acts as
a protein-bound prosthetic group in mitochondrial respiratory
chain complexes II, III, and IV and cytochrome c. The
administration of 5-ALA combined with sodium ferrous citrate
(SFC) enhance heme production, leading to respiratory
complex upregulation.[6] Thus, 5-ALA/SFC might be effective
for improving mitochondrial dysfunction and increasing the
production of ATP. Treatment with 5-ALA/SFC might also
improve insulin secretion by improving mitochondrial dys-
function. In fact, several studies showed beneficial effects of 5-
ALA on glycemic control in both prediabetic and diabetic
patients.[7–10]
We hypothesized that adding 5-ALA/SFC to insulin treatment
in patients with MDM may improve insulin secretion and
glycemic control. We, therefore, designed this study as the first
step in testing the effectiveness of 5-ALA/SFC as a treatment for
MDM. Herein, we describe the final study protocol (version 1.0;
April 24, 2020). The results of this study are expected to provide




This is a single-arm, open-label, pilot intervention study to
investigate the effects of 5-ALA/SFC in patients with MDM. We
created the present study design in accordance with Standard
Protocol Items: Recommendations for Interventional Trials and
Consolidated Standards of Reporting Trials 2010 guidelines.[11,12]
2.2. Study design
The study will be conducted at the Nagasaki University Hospital
in Japan. In total, 5 patients with MDM will be recruited to the
study, with a 24-week duration of intervention.
2.3. Ethical considerations
The study has been approved by the Certified Review Board
(CRB) of Nagasaki University (CRB approval no.: CRB20-012)
and is registered in the Japan Registry of Clinical Trials (https://
jrct.niph.go.jp) as jRCTs071200025. The study will be con-
ducted in accordance with the principles of the Declaration of
Helsinki,[13] Japan’s Clinical Trials Act (Act No. 16 of April 14,
2017), Japan’s Act on the Protection of Personal Information and
related regulatory notifications, and the present study protocol.
2.4. Study endpoints
2.4.1. Primary endpoint. Changes in glucose-stimulated insulin
secretion after the daily administration of 5-ALA/SFC for 24
weeks. To determine the changes, the values of area under the
curve of serum insulin levels from fasting (0minutes) to 120
minutes during 75-g oral glucose tolerance test (OGTT)
evaluated at 24weeks after the administration of 5-ALA/SFC
(week 24) will be compared to those at baseline (week 0).
2.4.2. Secondary endpoints. Changes in the following items
after the daily administration of 5-ALA/SFC for 24weeks: fasting
blood glucose, glycated hemoglobin, glycated albumin, values
obtained from the 75-g OGTT, values obtained from the flash
glucosemonitoring (FGM), and the required daily dose of insulin.
For each parameter, any change will be determined based on the
difference between the results at baseline (week 0) and those at
week 24.
2.4.3. Safety endpoints.All adverse events that occurred during
the trial will be recorded.
2.5. Participant recruitment
Participants will be recruited at the Nagasaki University Hospital.
The study will be fully explained to potential participants by
investigators; participants will then be asked to voluntarily sign an
informed consent form before their participation.
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2.6. Inclusion criteria
The study inclusion criteria are as follows:
(1) Patients aged ≥20years at the time of consent
(2) Outpatients
(3) Patients diagnosed with MDM who satisfy all of the
following main criteria and one or more of the sub-criteria
Main criteria
(1) Patients with diabetes mellitus being treated with insulin or
clinically requiring insulin therapy for glycemic control due to
decreased insulin secretion
(2) Patients complicated with neurosensory deafness
Sub-criteria
(1) Patients who have a family history of maternally inherited
diabetes mellitus
(2) Patients who show a level of serum lactate ≥ 18mg/dL
(2mmol/L) and/or a molar ratio of lactate to pyruvate
≥20
(3) Patients with short stature whose height is less than –2.0
standard deviation of Japanese adults
(4) Patients complicated with cardiomyopathy or cardiac
conduction abnormality
(5) Patients whose basal-ganglia and brainstem have bilaterally
symmetric abnormal lesions on computed tomography/
magnetic resonance imaging
(6) Patients who have had not changed their antidiabetic agent(s)
expect for insulin within 8weeks before the informed consent
is obtained
(7) Written informed consent
2.7. Exclusion criteria
The study exclusion criteria are as follows:
(1) Patients who have previously taken 5-ALA/SFC within 8
weeks before obtaining an informed consent
(2) Patients treated with metformin
(3) Patients with a history of porphyria, hemochromatosis, or
viral hepatitis
(4) Women who are currently pregnant or lactating
(5) Patients will not be compliant with a medically approved
contraceptive regimen during the study period
(6) Patients who participated in another clinical study within the
past 4 months
(7) Patients whom the investigators consider inappropriate for
participation
2.8. Withdrawal criteria
 Apatient may bewithdrawn from the study prematurely for the
following reasons:
 The patient asks to leave the trial.
 Continuing participation is inadvisable due to one or more
adverse events.
 5-ALA/SFCmust be withdrawn for ≥4weeks for any reason(s).
 The patient becomes pregnant.
 In the investigator’s opinion, continuation in the trial would be
detrimental to the patient’s well-being.
2.9. Study protocol
Participants withMDMwill be administered 5-ALA/SFC 100mg
twice a day (200mg/d) for 24weeks. An investigator will explain
the study protocol to each patient and, if consent is obtained, the
investigator will perform the observation/examination at the time
of registration in accordance with the description in Figure 1.
According to the inclusion and exclusion criteria, the investigator
will submit the participant’s registration form to the study
secretariat at the Department of Endocrinology andMetabolism,
Nagasaki University Hospital.
After the visit date, the investigator will continue to administer
5-ALA/SFC and conduct necessary examinations and surveys
until week 24 in accordance with the schedule in Figure 1. The
investigator will refer to the patient’s FGM result to adjust the
insulin dose based on his/her own judgement. During the study
period, any change of the drug or dose of antidiabetic agents
(except insulin) is prohibited.
To evaluate the patients’ glucose-dependent insulin responses,
a 75-g OGTT will be performed twice: before the start of the 5-
ALA/SFC regimen (week 0, 1st OGTT) and at 24weeks after the
start of the 5-ALA/SFC regimen (week 24, 2nd OGTT). When
patients need to bewithdrawn from the study for any reason, they
will undergo 75-g OGTT after discontinuing the 5-ALA/SFC.
Both OGTTs will be carried out under the condition of overnight
fasting. All antidiabetic agents including insulin and 5-ALA/SFC
will be held until the preceding day in each OGTT.
2.10. Laboratory measurements
The 2 OGTTs will use a 75-g glucose formulation, Trelan-G75
(AY Pharma, Tokyo). For each OGTT, the levels of plasma
glucose (mg/dL), serum insulin (mU/mL), serum C-peptide (ng/
mL), and plasma glucagon (pg/mL) will be measured at fasting (0
minutes) and at 30, 60, 120minutes after the ingestion of the
glucose load. We will also measure the serum levels of glycated
albumin, nonesterified fatty acid, leptin, adiponectin, high-
molecular-weight adiponectin, iron, unsaturated iron-binding
capacity, and ferritin at 0minutes. Urine specimens will be
obtained on each OGTT day for the measurement of the patient’s
albumin/creatinine ratio.
The levels of serum insulin and C-peptide will be measured by
the ECLusys kit (Roche, Basel, Switzerland). Blood samples for
plasma glucagon will be obtained using BD P800 tubes (BD,
Franklin Lakes, NJ). Plasma glucagon will be measured by a
sandwich ELISA kit (Mercodia, Uppsala, Sweden).
As shown in Figure 1, we will measure the patient’s complete
blood count and serum (plasma) levels of sodium, potassium,
chlorine, total cholesterol, high-density lipoprotein, cholesterol,
low-density lipoprotein, blood urea nitrogen, creatinine, total
bilirubin, aspartate aminotransferase, alanine aminotransferase,
alkaline phosphatase, g-glutamyl transpeptidase, creatine kinase,
glucose, and glycated hemoglobin at every visit of the study (week
0, 4, 8, 16, and 24), and (if withdrawing from the study) at early
discontinuation.
2.11. Adverse events
A serious adverse event is defined as any untoward medical event
that occurs at any dose, results in death, a life-threatening
condition, requires hospitalization, and results in significant
disability or incapacity.
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All serious adverse events occurring between the signing of the
informed consent form and the end of the trial will be
documented in the medical records and reported to the Minister
of Health, Labor, and Welfare (Japan) and the CRB by the
responsible investigator in accordance with Japanese regulations.
2.12. Data collection and management
The sponsor-investigator and sub-investigators will fill in all of
each patient’s data in a case report form (CRF). It is necessary that
all data recorded in the CRF are consistent with the original
material, unless data recorded directly in the CRF are used as the
source material. For the results of FGM, the output data signed by
the investigator will be regarded as the original material. During
the study, the investigators will collect data at each visit in accord
with the schedule in Figure 1. All data recorded in the CRF will be
checked by the data manager and will then be fixed/set. All study
findings anddocumentswill bemade confidential, andpatientswill
always be identified by their patient number, never by name.
Confidential patient-identifying documents will be maintained by
the investigators to preserve participant anonymity.
During the study, a sponsor-investigator will perform regular
site visits to review the protocol compliance, conduct source data
verification, assess drug accountability and management, and
assess laboratory procedures to ensure that the study is being
conducted according to all pertinent requirements.
2.13. Statistical analysis
The respective analysis sets are defined as follows. The intention
to treat (ITT) population is defined as all participants registered
for this trial; the safety analysis set (SAS) population is defined as
the participants in the ITT population with at least 1
administration of 5-ALA/SFC. The full analysis set (FAS)
population is defined as the participants in the SAS for whom
data after the administration of 5-ALA/SFC at one or more
scheduled visits are available. The per protocol set (PPS) is defined
as the participants in the FAS with the primary outcome measure.
The characteristics of all 5-ALA/SFC-treated populations will
be summarized using descriptive statistics on the ITT, SAS, FAS,
and PPS.
An efficacy analysis will be conducted using the FAS and PPS.
The primary endpoint and secondary endpoints listed above in
Section 2.4 will be estimated as point estimates and 95%
confidence intervals and summarized using descriptive statistics.
Safety endpoints will be analyzed in the SAS population.
Adverse events will be stratified by serious versus nonserious,
causal relationship, severity, and outcome. Analyses will be
categorized and tabulated, and a list will be formulated including
causality, extent, and outcomes.
Data containing missing values will be also included in the
analysis. Missing values will be imputed by a last observation
carried forward analysis. All data will be analyzed after being
fixed/set. All tests of significance will be done at a 2-tailed
significance level of 0.05. Data relevant to this clinical trial will be
analyzed using SAS, SPSS, R software, or JMP Pro 15 or higher.
3. Discussion
A nationwide case-finding study of genetically defined MDM
patients in Japan revealed that 86% of the patients required
insulin therapy due to the progressive insulin secretory disorder,
and 92% of them had sensorineural deafness.[1] Individuals with
MDM have advanced microvascular complications and mito-
chondria-related complications such as cardiomyopathy, cardiac
Figure 1. Treatment schedule and outcome measures. FGM=flash glucose monitoring, OGTT=oral glucose tolerance test.
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conductance disorders, neuromuscular symptoms, neuropsychi-
atric disturbance, and macular pattern dystrophy caused by
glycemic variability and higher oxidative stress levels.[14,15] To
prevent the development of those complications, therapy in
addition to insulin has been desired to directly improve the
mitochondrial dysfunction in patients with MDM.
Diagnostic criteria for mitochondrial disease were defined by
Japan Intractable Diseases Information Center,[16] but criteria
that are specialized for MDM have not been established. We set
main criteria as described in the inclusion criteria above based on
the results of the nationwide case-finding study.[1] We also set the
sub-criteria described above since that study also reported that
the rate of a family history of maternal inheritance was 68%,[1]
and the Japanese criteria for mitochondrial disease include items
such as a high serum lactate level, short stature, cardiomyopathy
or cardiac conduction abnormality, and bilateral symmetric
abnormal lesions in the basal ganglia and/or brainstem on
computed tomography/magnetic resonance imaging.
The administration of 5-ALA to healthy mice activate their
mitochondrial respiratory function by increasing the protein
expression and activity of cytochrome c oxidase (complex IV).[6]
In addition, Shimura et al. recently reported that 5-ALA/SFC
increased the oxygen consumption rate and ATP level via an
oxidative phosphorylation protein’s expression induced by
upregulations of heme, heme oxygenase-1, and the mtDNA
copy number in skin fibroblasts from individuals with mitochon-
drial disease.[17]
The administration of 5-ALA/SFC reduced blood glucose levels
and improved glucose tolerance in diabetic rodents by enhancing
mitochondrial function.[18,19] In prediabetic and diabetic human
subjects, the oral administration of 5-ALA/SFC also improved
their glucose tolerance, although the dosage regimen of 5-ALA/
SFC in those studies was lower than that of our present
investigation.[7–10] Our study could thus be expected to observe
improved effects on insulin secretory capacity and blood glucose
regulation by a recovery of the mitochondrial function. For the
evaluation of these effect, we will perform a 75-g OGTT before
and at 24weeks after the start of the administration of 5-ALA/
SFC and then compare the difference in insulin secretion.
The dosage of the investigational drug will be set at 100mg
taken orally twice daily (200mg/d) in accord with an ongoing
clinical trial for mitochondrial disease. That clinical trial was
registered in the Center for Clinical Trials, Japan Medical
Association (http://www.jmacct.med.or.jp) as JMA-IIA00358.
Another study conducted in patients with type 2 diabetes
(ClinicalTrials.gov NCT02481141) demonstrated the safety and
tolerability of the dose.[10] In studies using a similar dose of 5-
ALA, the adverse events were consistently mild, and some studies
did not observe any side effects. We consider that the 200mg/d
dose is acceptable and effective for patients with MDM.
There are some limitations in this trial.
(1) It will be conducted at a single center and the sample size is
small (n=5).
(2) It is a single-arm study and lacks a placebo control group.
(3) The follow-up period of the trial may be insufficient to lead to
a definitive conclusion regarding the improvement of insulin
secretion and glycemic control.
Despite these limitations, our research also has strengths. There
has been no study assessing the effect of 5-ALA/SFC on insulin
secretion and glycemic control in patients with MDM. We may
discover an effective antidiabetic agent for MDM according to
the pathology.
This trial will evaluate the effectiveness and safety of 5-ALA/
SFC in patients with MDM. It will test the potential effectiveness
of 5-ALA/SFC as adjunctive therapy for patients with MDM
receiving insulin therapy. The findings of the study are
expected to provide new treatment options for MDM and
improve the glycemic control and prognosis of patients with this
disorder.
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